Abstract
HepatoCellular Carcinoma (HCC) is the fifth most common cancer and the third most common cause of cancer- related deaths. In unresectable disease, chemotherapy has modest response rates without a clear improvement in overall survival. Sorafenib is a multikinase inhibitor that recently demonstrated improved overall survival in two randomized clinical trials. This review paper outlines the basic treatment options for HCC by stage, followed by a discussion of key issues in the treatment and management of patients with HCC: the use of targeted therapies and/or chemotherapy in metastatic disease and in different ethnic groups; the potential use of combination therapies in earlier disease stages; and the role of imaging in the era of targeted therapy and the associated challenges.
Keywords: Hepatocellular carcinoma, sorafenib, multikinase inhibitor, treatment
Current Drug Therapy
Title: Trends in the Treatment of Hepatocellular Carcinoma
Volume: 5 Issue: 2
Author(s): Janine M. Davies and Bert H. O'Neil
Affiliation:
Keywords: Hepatocellular carcinoma, sorafenib, multikinase inhibitor, treatment
Abstract: HepatoCellular Carcinoma (HCC) is the fifth most common cancer and the third most common cause of cancer- related deaths. In unresectable disease, chemotherapy has modest response rates without a clear improvement in overall survival. Sorafenib is a multikinase inhibitor that recently demonstrated improved overall survival in two randomized clinical trials. This review paper outlines the basic treatment options for HCC by stage, followed by a discussion of key issues in the treatment and management of patients with HCC: the use of targeted therapies and/or chemotherapy in metastatic disease and in different ethnic groups; the potential use of combination therapies in earlier disease stages; and the role of imaging in the era of targeted therapy and the associated challenges.
Export Options
About this article
Cite this article as:
M. Davies Janine and H. O'Neil Bert, Trends in the Treatment of Hepatocellular Carcinoma, Current Drug Therapy 2010; 5 (2) . https://dx.doi.org/10.2174/157488510791065111
DOI https://dx.doi.org/10.2174/157488510791065111 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
Call for Papers in Thematic Issues
Novel Therapeutic Approaches and Biomarkers for Chronic Kidney Disease (CKD)
The thematic issue on "Novel Therapeutic Approaches and Biomarkers for CKD" aims to provide a comprehensive exploration of cutting-edge strategies for the management of chronic kidney disease (CKD). This issue will delve into emerging therapeutic targets, focusing on critical aspects such as podocyte injury, endothelial dysfunction, and tubulointerstitial fibrosis, which ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Honey as a Source of Dietary Antioxidants: Structures, Bioavailability and Evidence of Protective Effects Against Human Chronic Diseases
Current Medicinal Chemistry Concerning Arterial Hypertension, Homocysteine and Paraoxonase-1
Current Hypertension Reviews Evaluation of the Anti-Hypercholesterolemic and Antioxidant Activity of Mentha pulegium (L.) Aqueous Extract in Normal and Streptozotocin- Induced Diabetic Rats
The Natural Products Journal Challenges in Vascular Repair by Endothelial Progenitor Cells in Diabetic Patients
Cardiovascular & Hematological Disorders-Drug Targets Arterial Stiffness and Cardiovascular Drugs
Current Pharmaceutical Design Pro-inflammatory Cytokines in Animal and Human Gestation
Current Pharmaceutical Design Chemoprotective Mechanism of the Natural Compounds, Epigallocatechin- 3-O-Gallate, Quercetin and Curcumin Against Cancer and Cardiovascular Diseases
Current Medicinal Chemistry Does Angiotensin Converting Enzyme Inhibitor Protect the Heart in Cardiac Surgery? From Laboratory to Operating Room: Clinical Application of Experimental Study
Current Pharmaceutical Design Oxidative/Nitrosative Brain Damage in Stress: Possible Target for Neuropsychopharmacological Drugs
Current Medicinal Chemistry - Central Nervous System Agents Statins in the Prevention of Cardiovascular Events in Patients with Renal Failure
Cardiovascular & Hematological Disorders-Drug Targets Developments in Imaging Technologies Related to Hypertensive Cardiovascular Diseases
Current Pharmaceutical Design Heme Oxygenase-1 in Vascular Smooth Muscle Cells Counteracts Cardiovascular Damage Induced by Angiotensin II
Current Neurovascular Research Endothelial Function and Pathogenesis of Endothelial Dysfunction
Current Immunology Reviews (Discontinued) The Therapeutic Potential of Rutin for Diabetes: An Update
Mini-Reviews in Medicinal Chemistry Reduction of Sodium Intake is a Prerequisite for Preventing and Curing High Blood Pressure in Hypertensive Patients - Second Part: Guidelines
Current Hypertension Reviews Periodontitis and Atherosclerosis, a Causal Relationship?
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 30 Years Lost in Anesthesia Theory
Cardiovascular & Hematological Agents in Medicinal Chemistry Molecular Basis of Cardioprotection by Erythropoietin
Current Molecular Pharmacology Substance-Related Disorders and Somatic Symptoms: How Should Clinicians Understand the Associations?
Current Drug Abuse Reviews A Randomized, Placebo-controlled, Triple-blind Study to Determine the Effect of Farlong Ginseng Plus® NotoGinseng Extract on Cholesterol and Blood Pressure
Current Nutraceuticals